MP51: Prostate Cancer: Staging

Poster Session Moderator(s)

• 

  Chad Ritch, MD, MBA

  Associate Professor
  University of Miami, Miller School of Medicine
• 

  Samuel Washington, III, MD

  Assistant Professor
  University of California, San Francisco
• 

  Kenneth Ogan, MD

  Emory University School of Medicine

Presentations:

• 4:30 PM – 5:45 PM

  MP51-01: How many lymph nodes could we save in prostate cancer staging lymphadenectomy?
  

  Poster Presenter: Javier Perez Ardavin, MD (he/him/his)
• 4:30 PM – 5:45 PM

  MP51-02: Prospective study to evaluate the prognostic value of nodal disease in prostate cancer?
  

  Poster Presenter: Javier Perez Ardavin, MD
• 4:30 PM – 5:45 PM

  MP51-03: Development of a Novel Nomogram to Identify Candidates for Extended Pelvic Lymph-Node Dissection in Prostate Cancer using MRI and PSMA PET
  

  Poster Presenter: Dennie Meijer
• 4:30 PM – 5:45 PM

  MP51-04: P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy
  

  Poster Presenter: Pontus Carl Röbeck, MD
• 4:30 PM – 5:45 PM

  MP51-05: Impact of clinical staging based on DRE vs imaging (TRUS/MRI) in a localized prostate cancer risk assessment nomogram
  

  Poster Presenter: Kevin Chang, BA
• 4:30 PM – 5:45 PM

  MP51-06: PIRADS score combined with positive core number on MRI-ultrasound fusion targeted prostate biopsy can predict the absence of pathological extraprostatic extension
  

  Poster Presenter: Masaki Kobayashi, MD – Tokyo Medical and Dental University
• 4:30 PM – 5:45 PM

  MP51-07: The prognostic value of the number of positive targeted cores in men with positive multiparametric magnetic resonance imaging of the prostate. Results from a large, multi-institutional series.
  

  Poster Presenter: Armando Stabile, MD – San Raffaele Hospital Milan Italy
• 4:30 PM – 5:45 PM

  MP51-08: Does a positive multi-parametric MRI always warrant prostate biopsy? The importance of integrating clinical and imaging data based on a large, multi-institutional series.
  

  Poster Presenter: Armando Stabile, MD – San Raffaele Hospital Milan Italy
• 4:30 PM – 5:45 PM

  MP51-09: The Utility of Novel Quantification Using Imaging Software for Analyzing Whole-Body Magnetic Resonance Imaging of Patients with Metastatic Prostate Cancer
  

  Poster Presenter: Yuki Kohada – TOHOKU MED & PHARM UNIVERSITY
• 4:30 PM – 5:45 PM

  MP51-10: Oncologic Outcomes after Radical Prostatectomy for Localized Prostate Cancer: Classification According to Prostate Magnetic Resonance Imaging Findings
  

  Poster Presenter: Gyoohwan Jung, MD – Seoul National University Bundang Hospital
• 4:30 PM – 5:45 PM

  MP51-11: Has the introduction of mpMRI in the diagnostic pathway of prostate cancer led to improved oncological outcomes after radical prostatectomy? Result from a large single-institutional series.
  

  Poster Presenter: Armando Stabile, MD – San Raffaele Hospital Milan Italy
• 4:30 PM – 5:45 PM

  MP51-12: The added value of microUS for the preoperative staging of prostate cancer: an update of a single-institutional prospective series
  

  Poster Presenter: Vittorio Fasulo, MD (he/him/his)
• 4:30 PM – 5:45 PM

  MP51-13: Fluorine-18 (18F) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) and the diagnosis and staging of primary prostate cancer (PCa)
  

  Poster Presenter: Matthew Henry Vincent Byrne, MBBS MRes – University of Oxford
• 4:30 PM – 5:45 PM

  MP51-14: Impact of 68Ga-PSMA PET/CT and Metastasis-Directed Therapy on Clinical Recurrence in Patients with Biochemical Recurrence after Radical Prostatectomy. Results from a Single Center Series
  

  Poster Presenter: Elio Mazzone
• 4:30 PM – 5:45 PM

  MP51-15: The role of ⁶⁸Ga-PSMA- and ⁶⁸Ga-DOTA-RM2 PET/MRI in the primary staging of high-risk Prostate Cancer patients undergoing radical prostatectomy. Preliminary results of a prospective, single center study.
  

  Poster Presenter: Paola Mapelli
• 4:30 PM – 5:45 PM

  MP51-16: The Risk of Recurrence in cN1 Prostate Cancer Patients treated with radical prostatectomy Varies According to the type Preoperative Staging. A comparison between 68Ga-PSMA-PET versus Conventional Imaging in a large, Multi-institutional Study
  

  Poster Presenter: Gabriele Sorce
• 4:30 PM – 5:45 PM

  MP51-17: Demographics and socioeconomic description of patients with prostate cancer in whom a prostate-specific membrane antigen PET was performed: a single-institution, retrospective analysis in NYC
  

  Poster Presenter: Juana Martinez, MD
• 4:30 PM – 5:45 PM

  MP51-18: Trends of primary staging for newly diagnosed prostate cancer – assessing the uptake of prostate specific membrane antigen positron emission tomography: A population based analysis
  

  Poster Presenter: Marlon L. Perera, MD – Austin Health
• 4:30 PM – 5:45 PM

  MP51-19: Pathologic Gleason Grade Group 1 in Black Men Implications for Renaming it "Not Cancer" in High-Risk Populations.
  

  Poster Presenter: Courtney Berg, DO – NYIT College of Osteopathi Medicine
• 4:30 PM – 5:45 PM

  MP51-20: The association of type and number of D'Amico high-risk criteria with rates of pathologically non organ confined prostate cancer
  

  Poster Presenter: Francesco Chierigo